

### Tozinameran

**S**

#### **Worsening of chronic graft-versus-host disease and steroid-refractory immune thrombocytopenia: 2 case reports**

In observational prospective cohort study of 106 patients conducted at the Rabin Medical Centre in Israel, two patients [sexes and ages *not stated*] were described, who developed worsening of chronic graft versus host disease (GvHD) or steroid-refractory immune thrombocytopenia following vaccination with tozinameran.

The patients had allogeneic haematopoietic cell transplantation and chronic GvHD. Thereafter, the patients received tozinameran [BNT162b2 COVID-19 vaccine, Pfizer-BioNTech; *routes and dosages not stated*]. Subsequently, one patient experienced worsening of moderate chronic GvHD related symptoms secondary to tozinameran and another patient with severe chronic GVHD experienced grade 4 steroid-refractory immune thrombocytopenia 2 weeks after the first vaccine [*outcomes of ADRs not stated; not all time to reaction onsets stated*].

Yeshurun M, et al. Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation. *Clinical Microbiology and Infection* 28: 303.e1-303.e4, No. 2, Feb 2022. Available from: URL: <https://www.journals.elsevier.com/clinical-microbiology-and-infection>

803661335